Biogen News and Research

RSS
Positive top-line results from Biogen Idec’s peginterferon beta-1a Phase 3 trial on RRMS

Positive top-line results from Biogen Idec’s peginterferon beta-1a Phase 3 trial on RRMS

Elan, Biogen Idec submit applications to FDA and EMA for updation of TYSABRI labels

Elan, Biogen Idec submit applications to FDA and EMA for updation of TYSABRI labels

Scientists develop playbook to end devastating impact of fibrotic diseases

Scientists develop playbook to end devastating impact of fibrotic diseases

Penn study suggests dopamine treatments may play role in increasing impulsivity

Penn study suggests dopamine treatments may play role in increasing impulsivity

Biogen Idec files rFIXFc BLA with FDA for treatment of hemophilia B

Biogen Idec files rFIXFc BLA with FDA for treatment of hemophilia B

Top-line results from Biogen Idec’s dexpramipexole Phase 3 trial on amyotrophic lateral sclerosis

Top-line results from Biogen Idec’s dexpramipexole Phase 3 trial on amyotrophic lateral sclerosis

Isis, Biogen Idec partner to discover and develop antisense drugs against neuromuscular disorders

Isis, Biogen Idec partner to discover and develop antisense drugs against neuromuscular disorders

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam third quarter 2012 revenues decrease to $16.8 million

AAPS recognizes top scientists in pharmaceutical sciences

AAPS recognizes top scientists in pharmaceutical sciences

Biogen Idec announces new data from BG-12 Phase 3 studies on RRMS

Biogen Idec announces new data from BG-12 Phase 3 studies on RRMS

Multiple sclerosis symptoms worse in those with low vitamin D levels

Multiple sclerosis symptoms worse in those with low vitamin D levels

Positive results from Sobi, Biogen Idec's rFIXFc Phase 3 trial on hemophilia B

Positive results from Sobi, Biogen Idec's rFIXFc Phase 3 trial on hemophilia B

Sleep disorder treatment: an interview with Dr Seth Lederman, President and CEO of Tonix Pharmaceuticals

Sleep disorder treatment: an interview with Dr Seth Lederman, President and CEO of Tonix Pharmaceuticals

Elan second quarter total revenue increases 6% to $288.0 million

Elan second quarter total revenue increases 6% to $288.0 million

Premier research institutions, Biogen Idec partner to sequence genomes of patients with ALS

Premier research institutions, Biogen Idec partner to sequence genomes of patients with ALS

EvaluatePharma releases World Preview 2018 report

EvaluatePharma releases World Preview 2018 report

Biogen Idec, MS community partner to celebrate Fourth Annual World MS Day

Biogen Idec, MS community partner to celebrate Fourth Annual World MS Day

Biogen Idec announces availability of two new AVONEX dosing innovations for MS

Biogen Idec announces availability of two new AVONEX dosing innovations for MS

EU and U.S. regulatory authorities accept Biogen Idec’s BG-12 NDA for review

EU and U.S. regulatory authorities accept Biogen Idec’s BG-12 NDA for review

PDL first quarter total revenues decrease to $77.3 million

PDL first quarter total revenues decrease to $77.3 million